Clinical Trial Update: A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing HLX10+HLX04 to sorafenib as first-line treatment in hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HLX04 (HLX04)
• HLX10
• Sorafenib (Sorafenib)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Hepatocellular Carcinoma (HCC) | Phase 3 | Status: WITHDRAWN